Ginkgo completed the acquisition of Zymergen for $300m.

Ginkgo, an American biotech company, completed the acquisition of Zymergen, an American biotechnology company, for $300m. "We have always had incredible respect for the Zymergen team and the strength of the technologies that they have built for cell programming. We are thrilled to integrate Zymergen's capabilities into our Foundry, which we expect to accelerate the growth of our platform as we continue to deliver on our mission to make biology easier to engineer for our customers, helping us drive down the costs of cell programming as we invest in scale. We can't wait to welcome Zymergen's technical teams, who will support our scaling objectives," Jason Kelly, Ginkgo Bioworks CEO and co-founder.